AR011503A1 - Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas - Google Patents
Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticasInfo
- Publication number
- AR011503A1 AR011503A1 ARP970101580A ARP970101580A AR011503A1 AR 011503 A1 AR011503 A1 AR 011503A1 AR P970101580 A ARP970101580 A AR P970101580A AR P970101580 A ARP970101580 A AR P970101580A AR 011503 A1 AR011503 A1 AR 011503A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- branched
- unbranched
- esters
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto seleccionado de las formulas I o II: donde R1 se selecciona de H, OH o de los ésteres C1-C12 (de cadena ramificada o no ramificada) o susalquil ésteres C1-C12 (de cadena ramificada o no ramificada o cíclica), o halogenos; oésteres halogenados C1-C4 que incluyen al trifluorometil éter ytriclorometil éter. R2, R3, R4, R5 y R6 se seleccionan independientemente de H, OH o ésteres de C1-C12(de cadena raqmificada o no ramificada o cíclica),halogenos o ésteres C1-C4halogenados incl uyendo al trifluorometil éter, ciano, alquil C1-C6(de cadena ramificada o no ramificada), o trifluorometil, con lacondicion de que cuando R1 es H, R2 no sea OH: X se selecciona de H, alquil C1-C6, ciano, nitro, trifluorometil,halogeno; n es 2 o 3; Y se selecciona de:a) la porcion (formula 3) donde R7 y R8 se seleccionan independientemente del grupo H, alquilo C1-C6, o fenilo opcionalmente sustituido por CN, alquilo C1-C6(de cadena ramificada o no ramificada), alcoxi C1- C6( de cadena ramif icada o no ramificada), halogeno, -OH, -CF3, o -OCF3; b)un heterociclo de cinco miembrossaturados, o no saturados o parcialmente no saturado que contiene hasta dos heteroátomos seleccionados del grupo formado por -O-, -NH-, - N(alquilo C1-C4)-,-N= y -S(O)m-, donde m es un entero entre 0-2, opcionalmente sustituido con 1-3 sustituyentes independientemente seleccionados del grupo formado porhidrogeno, hidroxilo, halo, alquilo C1-C4, trihalometilo, alcoxi C1-C4,trihalometoxi, acilox i C1-C4, alquiltio C1-C4, alquilsulfinil C1-C4,alquilsulfonil C1-C4, hidroxi alquilo (C1-C4), -CO2H-, -CN-, -CONHR1-, -NH2-, alquilamino C1-C4, dialquilamino (C1-C4), -CO2H-, -CN-, -CONHR1-, -NH2-,alquilamino C1-C4,dialquilamino (C1-C4), -NHSO2R1- , -NHCOR1-, -NO2, y fenilo opcionalmente sustituido con 1-3 alquilo (C1-C4); c) un heterociclo de seis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63397496A | 1996-04-19 | 1996-04-19 | |
US08/833,271 US5998402A (en) | 1996-04-19 | 1997-04-04 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AR011503A1 true AR011503A1 (es) | 2000-08-30 |
Family
ID=27092026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970101580A AR011503A1 (es) | 1996-04-19 | 1997-04-18 | Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0802183B1 (es) |
JP (1) | JP4093611B2 (es) |
KR (1) | KR100480193B1 (es) |
CN (1) | CN1106383C (es) |
AR (1) | AR011503A1 (es) |
AT (1) | ATE206701T1 (es) |
AU (1) | AU710149B2 (es) |
BR (1) | BRPI9715334B8 (es) |
CO (1) | CO4900051A1 (es) |
CY (2) | CY2325B1 (es) |
CZ (1) | CZ291701B6 (es) |
DE (2) | DE69707189T2 (es) |
DK (1) | DK0802183T3 (es) |
EA (1) | EA001448B1 (es) |
ES (1) | ES2162198T3 (es) |
FR (1) | FR09C0048I2 (es) |
HK (1) | HK1002863A1 (es) |
HU (1) | HU227077B1 (es) |
IL (1) | IL120701A (es) |
LU (1) | LU91608I2 (es) |
MX (1) | MX9702865A (es) |
NL (1) | NL300416I2 (es) |
NO (2) | NO309564B1 (es) |
NZ (1) | NZ314601A (es) |
PT (1) | PT802183E (es) |
SK (1) | SK281737B6 (es) |
UA (1) | UA48148C2 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172100B1 (en) | 1997-04-30 | 2001-01-09 | Eli Lilly And Company | Antithrombotic agents |
EP1019047B1 (en) | 1997-05-01 | 2003-11-05 | Eli Lilly And Company | Antithrombotic agents |
ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
AU3894399A (en) * | 1998-05-12 | 1999-11-29 | American Home Products Corporation | Benzocarbazole and indenoindole derived estrogenic agents |
US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
ID26890A (id) * | 1998-05-15 | 2001-02-15 | American Home Prod | 2-fenil-1-(4-(2-aminoetoksi) -benzil)-indol dalam kombinasinya dengan estrogen |
CN1309637A (zh) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | 包含2-苯基-吲哚化合物和雌激素制剂的组合物 |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
ES2213984T3 (es) * | 1998-10-30 | 2004-09-01 | Eli Lilly And Company | Derivados de azaindol y su uso como agentes antitrombicos. |
TWI220898B (en) * | 1999-03-04 | 2004-09-11 | Wyeth Corp | N-substituted indolines as estrogenic agents |
US6380185B1 (en) | 1999-03-04 | 2002-04-30 | American Home Products Corporation | N-substituted benzoyl indoles as estrogenic agents |
US6358943B1 (en) | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
AU3859400A (en) * | 1999-03-04 | 2000-09-21 | American Home Products Corporation | N-substituted benzoyl indoles as estrogenic agents |
WO2001019839A1 (en) * | 1999-09-13 | 2001-03-22 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
US6380166B1 (en) | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
EP1251855A1 (en) * | 2000-01-28 | 2002-10-30 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
WO2002003988A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
US20020022617A1 (en) * | 2000-07-06 | 2002-02-21 | American Home Products Corporation | Methods for increasing nitric oxide synthase activity |
WO2002003992A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
AU2001271706A1 (en) * | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Use of substituted indole compounds for treating breast disorders |
EP1656938A1 (en) | 2000-07-06 | 2006-05-17 | Wyeth | Combinations of SSRI and estrogenic agents |
AR030064A1 (es) * | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
US6509332B2 (en) | 2000-07-06 | 2003-01-21 | Wyeth | Methods of treating excessive intraocular pressure |
AU2001271781A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
CN1452497A (zh) | 2000-07-06 | 2003-10-29 | 惠氏公司 | Ssri和雌激素制剂的联合药物形式 |
EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
ATE321754T1 (de) | 2001-05-22 | 2006-04-15 | Lilly Co Eli | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
DK1401446T3 (da) | 2001-05-22 | 2005-05-23 | Lilly Co Eli | Tetrahydroquinolinderivater til inhiberingen af sygdomme forbundet med estrogenmangel eller med en urelgelmæssig fysiologisk reaktion til endogent estrogen |
NZ537051A (en) * | 2002-06-13 | 2007-11-30 | Wyeth Corp | Use of bazedoxifene in an extended dosage treatment regimen |
AU2003253129B2 (en) | 2002-07-22 | 2008-12-11 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
US7250440B2 (en) * | 2003-08-12 | 2007-07-31 | Wyeth | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents |
US7683051B2 (en) | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
US7683052B2 (en) | 2004-04-07 | 2010-03-23 | Wyeth | Crystalline polymorph of bazedoxifene acetate |
WO2005100315A1 (en) | 2004-04-08 | 2005-10-27 | Wyeth | Bazedoxifene ascorbate as selective estrogen receptor modulator |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するための方法 |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
BRPI0514119A (pt) * | 2004-08-05 | 2008-05-27 | Wyeth Corp | polimorfo cristalino de monoidrato de hidrocloreto de pipindoxifeno, composição, método de preparação da forma i polimórfica de hidrocloreto de pipindoxifeno, forma i polimórfica de hidrocloreto de pinpidoxifeno, método de conversão da forma i de monoidrato de hidrocloreto de pipindoxifeno na forma ii, métodos de tratamento de um mamìfero tendo uma doença ou sìndrome ou um distúrbio, métodos para reduzir colesterol, para inibir a perda óssea e para tratar cáncer de mama em um mamìfero,método de tratamento de uma mulher na pós-menopausa quanto a um ou mais distúrbios vasomotores,e , uso de um polimorfo |
AP2365A (en) | 2004-10-20 | 2012-02-20 | Endorech Inc | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women. |
FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
US20100087661A1 (en) * | 2007-02-12 | 2010-04-08 | Josef Jirman | Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
WO2009102773A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth | Methods of preparing polymorphic form a of bazedoxifene acetate |
RS54165B1 (en) | 2008-04-16 | 2015-12-31 | Karo Bio Ab | NEW LIGANDS FOR THE ESTROGENIC RECEPTOR |
CN102395561A (zh) * | 2009-04-13 | 2012-03-28 | 桑多斯股份公司 | 合成巴多昔芬乙酸酯及其中间体的方法 |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
ITMI20091109A1 (it) * | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
KR20200144591A (ko) | 2010-06-16 | 2020-12-29 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
US7968732B1 (en) | 2010-09-07 | 2011-06-28 | Divi's Laboratories, Ltd. | Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole |
US9212172B2 (en) | 2010-09-14 | 2015-12-15 | Dr. Reddy's Laboratories Limited | Preparation of crystalline bazedoxifene and its salts |
US8569483B2 (en) | 2011-06-21 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of bazedoxifene acetate and intermediates thereof |
CN102690225B (zh) * | 2012-04-11 | 2014-12-24 | 南京友杰医药科技有限公司 | 巴多昔芬的合成方法 |
JP2016518449A (ja) * | 2013-05-15 | 2016-06-23 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | インドール製剤を調製するためのプロセスおよび中間体 |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
RS64115B1 (sr) | 2014-03-28 | 2023-04-28 | Univ Duke | Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
CN107406424B (zh) * | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
KR20190110400A (ko) | 2018-03-20 | 2019-09-30 | 엠에프씨 주식회사 | 새로운 중간체를 이용한 바제독시펜의 제조방법 |
IT201800006562A1 (it) * | 2018-06-21 | 2019-12-21 | Procedimento e intermedi utili per la preparazione di indoli | |
IT201900001923A1 (it) | 2019-02-11 | 2020-08-11 | Erregierre Spa | Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato |
US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU373941A3 (es) * | 1970-01-21 | 1973-03-12 | ||
DE2557342A1 (de) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | Basisch substituierte indolderivate und verfahren zu ihrer herstellung |
US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
DE3232968A1 (de) * | 1981-09-10 | 1983-06-09 | Degussa Ag, 6000 Frankfurt | Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung |
CA1241660A (en) * | 1984-06-25 | 1988-09-06 | Yvan Guindon | Indole-2-alkanoic acids |
GB8707051D0 (en) * | 1986-04-15 | 1987-04-29 | Ici America Inc | Heterocyclic carboxamides |
DE3821148A1 (de) * | 1988-06-23 | 1989-12-28 | Erwin Von Dr Angerer | Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
GB9004301D0 (en) * | 1990-02-26 | 1990-04-18 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
US5051442A (en) * | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
WO1993023374A1 (en) * | 1992-05-08 | 1993-11-25 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
ATE188377T1 (de) * | 1993-06-29 | 2000-01-15 | Takeda Chemical Industries Ltd | Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose |
GB9326332D0 (en) * | 1993-12-23 | 1994-02-23 | Karo Bio | Indole derivatives |
DE4426625A1 (de) * | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
1997
- 1997-04-15 ES ES97302576T patent/ES2162198T3/es not_active Expired - Lifetime
- 1997-04-15 EP EP97302576A patent/EP0802183B1/en not_active Expired - Lifetime
- 1997-04-15 AT AT97302576T patent/ATE206701T1/de active
- 1997-04-15 NZ NZ314601A patent/NZ314601A/en not_active IP Right Cessation
- 1997-04-15 DK DK97302576T patent/DK0802183T3/da active
- 1997-04-15 DE DE69707189T patent/DE69707189T2/de not_active Expired - Lifetime
- 1997-04-15 PT PT97302576T patent/PT802183E/pt unknown
- 1997-04-15 DE DE122009000061C patent/DE122009000061I1/de active Pending
- 1997-04-15 SK SK472-97A patent/SK281737B6/sk not_active IP Right Cessation
- 1997-04-17 CZ CZ19971175A patent/CZ291701B6/cs not_active IP Right Cessation
- 1997-04-17 UA UA97041833A patent/UA48148C2/uk unknown
- 1997-04-17 AU AU18920/97A patent/AU710149B2/en not_active Expired
- 1997-04-18 CO CO97020584A patent/CO4900051A1/es unknown
- 1997-04-18 AR ARP970101580A patent/AR011503A1/es active IP Right Grant
- 1997-04-18 MX MX9702865A patent/MX9702865A/es unknown
- 1997-04-18 CN CN97113496A patent/CN1106383C/zh not_active Expired - Lifetime
- 1997-04-18 JP JP10156397A patent/JP4093611B2/ja not_active Expired - Lifetime
- 1997-04-18 HU HU9700777A patent/HU227077B1/hu active Protection Beyond IP Right Term
- 1997-04-18 NO NO971815A patent/NO309564B1/no not_active IP Right Cessation
- 1997-04-18 IL IL12070197A patent/IL120701A/xx active Protection Beyond IP Right Term
- 1997-04-18 KR KR1019970014894A patent/KR100480193B1/ko active IP Right Review Request
- 1997-04-18 EA EA199700044A patent/EA001448B1/ru not_active IP Right Cessation
- 1997-04-22 BR BRPI9715334A patent/BRPI9715334B8/pt not_active IP Right Cessation
-
1998
- 1998-03-10 HK HK98101958A patent/HK1002863A1/xx not_active IP Right Cessation
-
2003
- 2003-04-08 CY CY0300038A patent/CY2325B1/xx unknown
-
2009
- 2009-09-23 LU LU91608C patent/LU91608I2/fr unknown
- 2009-09-28 NL NL300416C patent/NL300416I2/nl unknown
- 2009-09-30 CY CY2009016C patent/CY2009016I2/el unknown
- 2009-09-30 FR FR09C0048C patent/FR09C0048I2/fr active Active
- 2009-11-09 NO NO2009025C patent/NO2009025I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR011503A1 (es) | Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas | |
AR006705A1 (es) | Compuestos de 3-[4-(2-fenil-indol-1-ilmetil)-fenil]-acrilamida y 2-fenil-1-[4-(amino-1-il-alqu-1-inil)-bencil]-1h-indol-5-ol, metodo para preparar medicamentos y composiciones farmaceuticas que los contiene | |
ES2033423T3 (es) | Procedimientos para preparar derivados de 2-fenilpurinona. | |
ES2100151T3 (es) | Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos. | |
ES2142798T3 (es) | Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR020074A1 (es) | COMPOSICIoN FARMACÉUTICA DE 2-FENIL-1-[4-(2-AMINOETOXI)BENCIL]-INDOL Y ESTRoGENO, Y,SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO | |
MX9300498A (es) | Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ES2079719T3 (es) | Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes. | |
UY24555A1 (es) | Nuevos compuestos | |
AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
EA200200360A1 (ru) | Производные пурина | |
ATE29255T1 (de) | Succinimid-derivate und deren herstellung. | |
AR015183A1 (es) | Ariloxi-alquil-dialquilaminas y procesos para su produccion | |
ES526318A0 (es) | Procedimiento para la obtencion de derivados de 1-hidroxietil-triazolilo sustituidos | |
AR030064A1 (es) | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos | |
BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
FI894061A (fi) | Menetelmä lääkeaineina käyttökelpoisten , -disubstituoitujen N-sykloalkyylialkyylibentsyyliamiinien valmistamiseksi ja niiden synteesivälituotteita | |
CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
MX9306529A (es) | Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene | |
AU643290B2 (en) | Derivatives of 2-aminoalkyl-5-arylalkyl-1,3-dioxanes, their preparation and their therapeutic application | |
ATE204278T1 (de) | Serotoninergische ergolin derivate | |
DK435583D0 (da) | Fremgangsmade til fremstilling af heterocykliske derivater af cyklobutan | |
AR022797A1 (es) | Benzoil indoles n-sustituidos como agentes estrogenicos | |
ES2179009T3 (es) | Nuevos compuestos indolicos su utilizacion para el teñido y el maquillaje de las materias queratinicas, composiciones que los contienen y procedimientos de teñido. | |
ES2052266T3 (es) | Empleo de mezclas de poliglicoleteres como antiespumantes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |